Clinical Trial Update: Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD [Phase 3]

View source ↗

Summary

A Phase 3 efficacy and safety study of Symbicort Turbuhaler in Chinese patients with chronic obstructive pulmonary disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Symbicort Turbuhaler (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED